Screener
Jazz Pharmaceuticals JAZZ Acquisition accounting inventory fair value step-up adjustment
Acquisition accounting inventory fair value step-up adjustment at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept jazz:InventoryStepUpValueAdjustment.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
| Intangible asset amortization | 172.3 | 154.4 |
| Share-based compensation | 74.5 | 67.7 |
| Acquisition accounting inventory fair value step-up adjustment | 37.5 | 29.9 |
| Provision for losses on accounts receivable and inventory | 14.2 | 5.3 |
| Depreciation | 9.1 | 10.4 |
| Non-cash interest expense | 4.7 | 17.1 |
| Deferred tax benefit | (66.2) | (43.8) |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's acquisition accounting inventory fair value step-up adjustment?
- Jazz Pharmaceuticals (JAZZ) reported acquisition accounting inventory fair value step-up adjustment of $37.5M in Q1 2026.
- How has Jazz Pharmaceuticals's acquisition accounting inventory fair value step-up adjustment changed year-over-year?
- Jazz Pharmaceuticals's acquisition accounting inventory fair value step-up adjustment increased by 25.4% year-over-year, from $29.9M to $37.5M.
- What is the long-term trend for Jazz Pharmaceuticals's acquisition accounting inventory fair value step-up adjustment?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's acquisition accounting inventory fair value step-up adjustment has grown at a -9.8% compound annual growth rate (CAGR), from $223.09M to $147.95M.
- What does acquisition accounting inventory fair value step-up adjustment mean?
- This adjustment reflects the fair value step-up of inventory acquired in a business combination, which is subsequently expensed as the inventory is sold. It is a non-cash accounting adjustment that reconciles the difference between the acquired inventory's historical cost and its fair value at the time of acquisition. This metric helps investors isolate the impact of acquisition accounting on cost of goods sold.
Ask your AI about Jazz Pharmaceuticals's acquisition accounting inventory fair value step-up adjustment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude